The MHRA Yellow Card scheme and pharmacovigilance for research contexts

The Yellow Card scheme is the United Kingdom's system for collecting reports of suspected adverse drug reactions (ADRs), adverse incidents involving medical devices, and defective or falsified medicines, administered by the MHRA. It is the same underlying mechanism, now largely digital via the Yellow Card website and app, that has operated in various forms since it was established following the thalidomide tragedy of the early 1960s, and it remains the primary post-marketing surveillance tool for medicines in active use across the UK.

The scheme's scope is worth stating precisely rather than assuming. It is designed to capture suspected adverse reactions to medicines and vaccines, whether licensed or unlicensed, when they are administered to a human being — the reporting obligation is not restricted only to licensed products. Healthcare professionals, and since a scheme expansion some years ago, patients and carers directly, can submit reports; the obligation is formally strongest for healthcare professionals and marketing-authorisation holders, with mandatory reporting duties attaching to the latter for products they hold a licence for.

This creates a specific and easily misunderstood situation for unlicensed 'research peptides' as discussed elsewhere in this catalogue's UK regulatory overview. None of the longevity peptides covered on this site holds a UK marketing authorisation, and none has a marketing-authorisation holder with a corresponding mandatory reporting duty under the scheme. This does not mean adverse events involving these substances fall outside Yellow Card's scope entirely — a healthcare professional who becomes aware of a suspected adverse reaction in a patient, regardless of the substance's licensing status, can and generally should submit a report — but it does mean the systematic, obligation-driven surveillance that exists for licensed medicines does not exist in the same form for this class of substance.

The practical consequence is a pharmacovigilance gap specific to unlicensed research substances. Where a licensed medicine generates a steady, legally mandated stream of ADR reports feeding into MHRA signal-detection processes, an unlicensed research peptide generates reports only opportunistically, when a clinician happens to make the connection and chooses to file one. This is part of why the adverse-event evidence base for compounds such as BPC-157 or TB-500, used in a research-only or off-label context, remains thin relative to their apparent popularity in some research and self-experimentation communities.

Thymosin Alpha-1 and SS-31 sit in a partially different position given their more advanced regulatory status discussed elsewhere on this site — Tα1 licensed in 30+ other jurisdictions, SS-31 in active registered clinical trials. Adverse events occurring within a registered clinical trial follow the trial's own pharmacovigilance protocol (with mandatory expedited reporting of serious adverse events to the relevant ethics committee and regulator) rather than routing through Yellow Card directly, though signals from trial data can and do inform the wider regulatory picture that Yellow Card also feeds into.

For a UK-based research programme working with unlicensed peptides, the practical pharmacovigilance question is not whether Yellow Card applies in a formal sense, but whether the programme has its own internal adverse-event capture and escalation process, since reliance on the national scheme alone will systematically under-detect signals for substances outside its main reporting flow. Institutional research ethics frameworks typically require exactly this kind of internal safety-monitoring plan as a condition of approval, independent of whatever external reporting scheme might also apply.

A further relevant MHRA mechanism, distinct from Yellow Card itself, is the Suspected Unexpected Serious Adverse Reaction (SUSAR) reporting requirement that applies specifically within Clinical Trials of Investigational Medicinal Products (CTIMPs) regulated under the Medicines for Human Use (Clinical Trials) Regulations 2004. Any UK research programme intending to move a peptide from informal research use toward a registered clinical trial needs to plan for this SUSAR framework specifically, as it operates on a different timeline and threshold than routine Yellow Card reporting.

None of this constitutes legal advice for a specific research programme, and any UK-based group working with unlicensed peptides in a context involving human participants should seek its own regulatory and ethics guidance rather than relying on a general summary. The purpose here is narrower: to make clear that Yellow Card's applicability to unlicensed research substances is real but structurally weaker than for licensed medicines, and that this gap is a planning consideration rather than a reason to assume no reporting mechanism exists at all.

The research implication is that any programme working with the peptides covered on this catalogue should treat proactive internal pharmacovigilance — structured adverse-event logging, a clear escalation path, and voluntary Yellow Card submission where a suspected reaction is identified — as a standard part of research protocol design, precisely because the systematic external mechanism that exists for licensed medicines does not extend to this class of substance in the same automatic way.